National Psoriasis Foundation awards 12 psoriasis and psoriatic arthritis research fellowships

July 02, 2013

PORTLAND, Ore. (July 1, 2013)--Twelve residents and medical students each received a one-year, $40,000 National Psoriasis Foundation fellowship to study psoriasis and psoriatic arthritis. The National Psoriasis Foundation Amgen Medical Dermatology Fellowships aim to increase the number of scientists studying and treating psoriatic diseases by encouraging promising doctors to dedicate their careers to psoriasis and psoriatic arthritis as physician researchers.

The fellowships connect an early-career doctor with an established psoriatic disease researcher who will oversee their work. Learn more about the Psoriasis Foundation fellowship program: http://www.psoriasis.org/fellowships. The 2013 fellows are: "These exciting projects, ranging from the impact of diet on psoriasis to the safety and performance of treatments in real life, are critical to answering questions about the causes of psoriatic diseases and how they can be stopped," said Randy Beranek, National Psoriasis Foundation president and CEO. "We launched this fellowship initiative because we know the future generation of researchers is the key to curing psoriasis and psoriatic arthritis."
-end-
The Psoriasis Foundation fellowships are supported by a grant from Amgen.

About the National Psoriasis Foundation

National Psoriasis Foundation is the world's largest nonprofit organization serving people with psoriasis and psoriatic arthritis. Our mission is to find a cure for psoriasis and psoriatic arthritis and to eliminate their devastating effects through research, advocacy and education. For more information, call the Psoriasis Foundation, headquartered in Portland, Ore., at 800.723.9166, or visit http://www.psoriasis.org. Follow the Psoriasis Foundation on Facebook and Twitter.

National Psoriasis Foundation

Related Psoriasis Articles from Brightsurf:

Most psoriasis patients taking immunosuppressants survive COVID-19
Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19.

Getting under the skin of psoriasis
Psoriasis afflicts millions of people worldwide, but treatments are limited to small molecules like steroids, which can cause skin thinning and lose their effectiveness over time.

Psoriasis patients' mental health is more than skin-deep
A new study from Umeå University, Sweden, shows that other somatic diseases have even more impact on patients' mental health than their skin symptoms, highlighting the importance of holistic patient care.

Psoriasis: Towards a novel therapeutic approach
Researchers at the Université libre de Bruxelles (ULB) and the Department of Dermatology of the Erasme hospital uncover the importance of VEGFA signaling in the epidermis to mediate psoriasis development.

Insights into psoriasis suggest a new treatment target
Investigators from Brigham and Women's Hospital and the Harvard Stem Cell Institute have uncovered a novel pathway that may explain why skin thickens in psoriasis and suggests new strategies for developing therapies for the condition.

Psoriasis onset determines if psoriatic arthritis patients develop arthritis or psoriasis first
In a new study presented at the 2019 ACR/ARP Annual Meeting, researchers found the age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis.

Study: Some biologic treatments for psoriasis may be safer for patients
In the largest study of its kind, Erica D. Dommasch, M.D., M.P.H., a dermatologist in the Department of Dermatology at BIDMC, and colleagues found a decreased risk of infection in patients with psoriasis using some of the newer, more targeted medications compared to those taking methotrexate, a drug widely used since the 1960s as a first line treatment for moderate-to-severe psoriasis.

Higher weight increases risk of psoriasis
The higher a person's BMI, the greater the chance of getting psoriasis.

Lipid that aids normal skin turnover may help psoriasis
Topical application of the lipid phosphatidylglycerol, or PG, on a mouse model of psoriasis reduced inflammation as well as characteristic, raised skin lesions, they report in the Journal of Investigative Dermatology.

New insight into the mechanism of the drug against sclerosis and psoriasis
A multidisciplinary research team at Aarhus University has provided fundamental new insight into the mechanism of the medical drug dimethyl fumarate, which is the active component of important treatments for multiple sclerosis and psoriasis.

Read More: Psoriasis News and Psoriasis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.